Reports of anaphylaxis after Pfizer, Moderna vaccines
Editor's Note Since emergency use authorization of the Pfizer-BioNTech and Moderna vaccines in December, the Centers for Disease Control and Prevention’s Vaccine Adverse Event Reporting System (VAERS) has received reports of allergic reactions including anaphylaxis. From December 14, 2020, through January 18, 2021, 9,943,247 doses of the Pfizer vaccine and…
White House invokes wartime powers to increase production of vaccines, at-home tests, surgical gloves
Editor's Note In a February 5 media briefing, the White House says it has invoked the Defense Production Act to help Pfizer produce more of its COVID-19 vaccine, and the same will hold true for Johnson & Johnson, should it receive Emergency Use Authorization for it’s vaccine, the February 5…
CDC: New COVID-19 cases have declined 13.4% since January 8
Editor's Note Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), said on February 3 that new COVID-19 cases in the US had fallen to pre-Thanksgiving levels, and the infection rates were continuing to decline, the February 3 The Hill reports. COVID-19 cases and hospital admissions appear…
Pharmacies to get 1 M COVID-19 vaccine doses next week
Editor's Note On February 11, the federal government will begin distributing 1 million doses of COVID-19 vaccines to 6,500 retail pharmacy stores, and this could expand to some 40,000 stores, according to a February 2 statement from the White House. These doses are in addition to the 10.5 million that…
CDC: Anaphylactic reactions after first dose of Pfizer-BioNTech vaccine
Editor's Note From December 14 to 23, 2020, after administration of 1,893,360 first doses of the Pfizer-BioNTech COVID-19 vaccine, the Centers for Disease Control and Prevention (CDC) identified 21 case reports of anaphylaxis. Of those, 4 (19%) were hospitalized (including 3 in intensive care), and 17 (81%) were treated in…
Study provides evidence that vaccines protect against new COVID-19 variants
Editor's Note A study, led by researchers from Rockefeller University in New York City, finds that volunteers vaccinated with either the Moderna or the Pfizer/BioNTech vaccine will be protected against new variants of the COVID-19 virus. The researchers tested plasma taken from 20 volunteers who had received both doses of…
Willingness of US adults to get the COVID-19 vaccine
Editor's Note This study led by researchers from the Virginia Commonwealth University, Richmond, finds that COVID-19 vaccine-related messaging should address concerns about the vaccine and its development and reinforce its benefits to increase the willingness of US adults to get the COVID-19 vaccine and to get the vaccine under an…
J&J’s single-dose COVID-19 vaccine has good safety profile
Editor's Note Results from Johnson & Johnson’s early-stage trials for its COVID-19 vaccine showed neutralizing antibodies in all participants who received the vaccine when they were tested at 57 days. The J&J Ad26.COV2.S vaccine is different than the Pfizer-BioNTech and Moderna vaccines in that it is anenovirus-based rather than mRNA-based.…
Supply chain strategies shift to meet pandemic-induced demands
Resiliency, a term that has cropped up repeatedly during the COVID-19 pandemic, is often considered a key defense against burnout. But it is also important in the context of the healthcare supply chain, says Ed Hisscock, senior vice president of supply chain management at Trinity Health, a 22-state healthcare system…
Editorial
The rollout of COVID-19 vaccines starting in December 2020 was the one bright spot in an otherwise tragic year with a rapidly rising death toll currently over 385,000. Distribution of the 20 million doses promised by year end was thwarted by problems such as lack of coordination and lack of…
